TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00624611

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Residual pump blood management post aortic cannula removal
Description: Residual pump blood will be maximally hemoconcentrated by further ultrafiltation within the CPB machine. Resulting hematocrit will be approximately 0.4. The total residual pump blood volume, approximately 300ml, will be reinfused over one hour, beginning 15 minutes after removal of the aortic cross clamp. Additional protamine sulfate will be given every 30 minutes during the infusion, .03 mg/ml of residual pump blood. Procedures in this group do not deviate from current standard practice.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Residual pump blood management post aortic cannula removal
Description: All residual pump blood will be processed with a bedside red cell washing device (Cell Saver). The resulting total volume of concentrated red cells will be infused over one hour, beginning 15 minutes after removal of the aortic cross clamp. Administration of additional protamine is not required due to the low concentrations of heparin in the resulting product.
Study: NCT03422328

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: macitentan
Description: macitentan 10 mg, film-coated tablet, oral use
Study: NCT02875405

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Posterior left pericardiotomy
Description: Patient will receive a posterior left sided pericardiotomy. The incision will be made posterior to the phrenic nerve and run from the inferior left pulmonary vein to the diaphragm.
Study: NCT01864109

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: G-CSF
Description: G-CSF-to be administered after the completion of appropriate chemotherapy cycles as per institutional guidelines.
Study: NCT02694094

Intervention type: DIETARY_SUPPLEMENT
Intervention: Modified Atkins or Ketogenic Diet
Description: Biochemical and vascular parameters will be compared from adults who have been on ketogenic diet therapy for \> 12 months to adults naive to ketogenic diet therapy. In addition, adults naive to diet therapy who subsequently begin diet therapy will have these same parameters followed over time.
Study: NCT02932410

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Macitentan
Description: Dispersible tablet; Oral use

Intervention type: OTHER
Group type: OTHER
Intervention: Standard-of-care
Description: Standard-of-care as per site's clinical practice which may comprise treatment with PAH non-specific treatment and/or up to two PAH-specific medications excluding macitentan and IV/SC prostanoids.
Study: NCT02784210

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methylprednisolone
Description: 3 days of corticosteroids (intravenous methylprednisolone at 1000 mg/day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: 3 days of corticosteroids (oral prednisone at 1250 mg/day
Study: NCT01973322

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: arm 1: DC Vaccine + RT
Description: three daily doses of 8 Gy up to 12 Gy delivered to one non-index metastatic field between vaccine doses 1 and 2 (optional to one additional field between vaccine doses 7 and 8) utilizing IMRT-IMAT techniques

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: arm 2: DC Vaccine + IFN-alfa
Description: daily 3 MU subcutaneous IFN-alfa for 7 days before leukapheresis (day -15 to -9, and for 7 days before any other additional leukapheresis)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: arm 3: both arm 1 and 2 + RT
Description: both 1 and 2 external immunostimulant conditions (Intradermal Autologous Dendritic Cell Vaccine + 3 single boosts of RT + IFN-alfa, 3 MU daily for 7 days before leukapheresis)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: arm 4: DC Vaccine
Description: neither 1 or 2 external immunostimulant conditions (only Intradermal Autologous Dendritic Cell Vaccine)
Study: NCT03262779

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: combination nivolumab and ipilimumab
Description: Combination therapy with nivolumab 3 mg/kg administered intravenously (IV) every 2 weeks, with ipilimumab 1 mg/kg administered IV every 6 weeks.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: combination nivolumab and ipilimumab
Description: Combination therapy with nivolumab 3 mg/kg administered intravenously (IV) every 2 weeks, with ipilimumab 1 mg/kg administered IV every 6 weeks.
Study: NCT02799186

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: blood sample for genetic analysis
Study: NCT01059643

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY2523355
Description: Dose determined by participant body surface area: 5 milligrams/square meter(mg/m²) or 6 mg/m², administered intravenously as a 1-hour infusion on Days 1, 2 and 3 of a 21 day cycle; for up to 2 cycles (4 cycles for prostate cancer patients). Additional cycles administered based on patient response assessment.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pegfilgrastim
Description: 6 milligrams (mg), administered subcutaneously approximately 24 hours after third dose of LY2523355 on Day 4 of each 21-day cycle, for up to 2 cycles of LY2523355 administration (4 cycles for prostate cancer patients). Additional cycles of LY2523355 administered based on patient response assessment.
Study: NCT03860961

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Survivorship Care Plan (SCP)
Description: Given survivorship care plan

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Survivorship Care Plan (SCP)
Description: Given survivorship care plan

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Treatment Plan
Description: Given treatment plan
Study: NCT03737201

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ozone
Description: In the two-visit indirect pulp therapy, due to reduce the number of bacteria remaining in the cavity, the antimicrobial agents can be used as cavity disinfectants such as ozone.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: chlorhexidine digluconate
Description: In the two-visit indirect pulp therapy, due to reduce the number of bacteria remaining in the cavity, the antimicrobial agents can be used as cavity disinfectants such as chlorhexidine digluconate.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control
Description: without any cavity disinfectant
Study: NCT03295903

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Cannabidiol supplement
Description: Subjects will be administered in a double-blinded, randomized and cross-over design

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Cannabidiol supplement
Description: Subjects will be administered in a double-blinded, randomized and cross-over design

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Cannabidiol supplement
Description: Subjects will be administered in a double-blinded, randomized and cross-over design

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Cannabidiol supplement
Description: Subjects will be administered in a double-blinded, randomized and cross-over design

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Cannabidiol supplement
Description: Subjects will be administered in a double-blinded, randomized and cross-over design
Study: NCT03978910

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: measurements of the accuracy of the reaching movements
Description: Euclidian distance between final position and target
Study: NCT02835872

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: dietary fiber
Description: Fiber containing drink mixes and crackers to be consumed with meals (1g fiber/serving) three times per day for a total of 3 g fiber.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: dietary fiber
Description: Fiber containing drink mixes and crackers to be consumed with meals (1g fiber/serving) three times per day for a total of 3 g fiber.
Study: NCT01406704

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rosiglitazone
Description: Rosiglitazone (8 mg/day)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: alpha-lipoic acid
Description: alpha-lipoic acid (1800 mg/day)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rosiglitazone/alpha-lipoic acid
Description: combination of Rosiglitazone (8 mg/day) and Thioctic acid (1800 mg/day)
Study: NCT02437825

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: octreotide
Description: Octreotide has been in clinical use for thirty years and approved for use in Israel in acromegaly and functional gastroenteropancreatic tumours. It is currently being used extensively in surgical patients to prevent pancreatic fistulae1, and in lymphorrhea (both lymphatic malformations and leaks from the thoracic duct)

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo ( saline) act as comperator in this study.
Study: NCT01390714

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: E3710
Description: Arm A:~1. E3710 40 mg→RPZ 10 mg→E3710 20 mg~2. RPZ 10 mg→E3710 20 mg→E3710 40 mg~3. E3710 20 mg→E3710 40 mg→RPZ 10 mg~Crossover study of E3710 40 mg, E3710 20 mg, and PRZ 10 mg, once daily, for 5 days, oral administration.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: E3710
Description: Arm B:~1. E3710 40 mg→E3710 80 mg→EPZ 40 mg~2. E3710 80 mg→EPZ 40 mg →E3710 40 mg~3. EPZ 40 mg→E3710 40 mg→E3710 80 mg~Crossover study of E3710 40 mg, E3710 80 mg, and EPZ 40 mg, once daily, for 5 days, oral administration.
Study: NCT03997708

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Med-LFD
Description: All participants of this group at phase 1 (elimination phase), will initially follow the Med- LFD (2-6 weeks). At phase 2 (reintroduction phase), patients will gradually reintroduce foods rich in FODMAPs (6-8 weeks) and test their tolerance. At phase 3 (maintenance phase), following the reintroduction of foods rich in FODMAPs, patients will follow an individualized diet based on their personal tolerance (a combination of high and low FODMAPs).
Study: NCT00878254

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Rituximab 375 mg/m\^2 intravenously (IV) on Day 1 for 4 Cycles, per study protocol. For study participants achieving complete remission, during maintenance therapy every 6 months for up to three years, per study protocol.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Cyclophosphamide 800 mg/m\^2 IV on Day 1 and 200 mg/m\^2 IV on Days 2 through 5 of Cycles 1 and 3, per study protocol.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytarabine
Description: Cytarabine 2 grams/m\^2 IV on Days 1 and 2 of Cycles 2 and 4, per study protocol.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin
Description: Doxorubicin 45 mg/m\^2 IV bolus Day 1 of Cycles 1 and 3, per study protocol.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide
Description: Etoposide 60 mg/m\^2 IV on Days 1 through 5 of Cycles 2 and 4, per study protocol.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ifosfamide
Description: Ifosfamide 1.5 grams/m\^2 IV on Days 1 through 5 of Cycles 2 and 4, per study protocol.
Study: NCT03997708

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Nutritional Guidelines of the British National Institute for Health and Care Excellence (NICE) Managing IBS
Description: All participants of this group will be informed to follow a diet based on the nutritional guidelines of the British National Institute for Health and Care Excellence (NICE) for Managing IBS for 4 weeks.
Study: NCT01107249

Intervention type: DEVICE
Group type: OTHER
Intervention: Boston Scientific Ultraflex or Wallstent stents
Description: Stent used to maintain luminal patency in esophageal strictures and occlude esophageal fistulas to reduce gastric leaks, perforations and/or fistulas.
Study: NCT01785771

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ITCA 650 (exenatide in DUROS)
Study: NCT00577018

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prucalopride
Description: 4 mg o.d.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prucalopride
Description: 1 mg o.d. for 2 days, 2 mg o.d. for 2 days and 4 mg o.d. thereafter
Study: NCT00721708

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: pure carnosine
Description: one time dose of pure carnosine (450 mg)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Beef
Description: one time dose, 150 g of beef

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Chicken
Description: One time dose, 150g of chicken breast
Study: NCT00878254

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leucovorin
Description: Leucovorin: 100 mg/m\^2 IV beginning 36 (+/-4) hours after start of Methotrexate infusion, and then 10 mg/m\^2 at 6 hour (+/- 30 min) intervals until Methotrexate level is \< 0.1 µmol/L during Cycles 1 and 3 per study protocol.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mesna
Description: Mesna 360 mg/m\^2 IV on Days 1 through 5 of Cycles 2 and 4, per study protocol.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate
Description: Methotrexate 1,200 mg/m\^2 in 250 mL D5W IV over 1 hour, followed by Methotrexate 3,000 mg/m\^2 in 1,000 mL D5W by continuous infusion over 23 (+/-2) hours on Day 10 of Cycles 1 and 3, per study protocol.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vincristine
Description: Vincristine 1.5 mg/m\^2 IV push (maximum of 2 mg) on Days 1 and 8 of Cycles 1 and 3, per study protocol.
Study: NCT03104322

Intervention type: OTHER
Group type: OTHER
Intervention: patientMpower platform
Description: electronic health journal for patient to record compliance, spirometry, impact on daily life and symptoms

Intervention type: OTHER
Group type: OTHER
Intervention: usual care
Description: usual care
Study: NCT03755414

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Stem cell transplantation
Description: Standard of care

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Stem cell transplantation
Description: Standard of care

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Itacitinib
Description: Itacitinib may be taken without regard to food.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Itacitinib
Description: Itacitinib may be taken without regard to food.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Functional Assessment of Cancer Therapy-Bone Marrow Transplant (FACT-BMT)
Description: * Screening, day 14, day 28, day 42, day 74, day 100, taper period, and follow-up (pilot study)~* Screening, day 14, day 28, day 42, day 74, day 100, day 180, taper period, and follow-up period (expansion study)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Functional Assessment of Cancer Therapy-Bone Marrow Transplant (FACT-BMT)
Description: * Screening, day 14, day 28, day 42, day 74, day 100, taper period, and follow-up (pilot study)~* Screening, day 14, day 28, day 42, day 74, day 100, day 180, taper period, and follow-up period (expansion study)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Human Activity Profile
Description: * Screening, day 14, day 28, day 42, day 74, day 100, taper period, and follow-up (pilot study)~* Screening, day 14, day 28, day 42, day 60, day 74, day 100, day 180, taper period, and follow-up period (expansion study)
Study: NCT00577018

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: o.d.
Study: NCT03755414

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Human Activity Profile
Description: * Screening, day 14, day 28, day 42, day 74, day 100, taper period, and follow-up (pilot study)~* Screening, day 14, day 28, day 42, day 60, day 74, day 100, day 180, taper period, and follow-up period (expansion study)
Study: NCT03078010

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Piperacillin-tazobactam
Description: piperacillin-tazobactam (4.5 gm IV q 6 hrs)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cefepime
Description: (2 gm IV q 8 hrs)
Study: NCT03745287

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CTX001
Description: Administered by IV infusion following myeloablative conditioning with busulfan.
Study: NCT03379623

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ESCAPE-pain Programme
Description: The Enabling Self-management and Coping with Arthritic (knee) Pain using Exercise (ESCAPE-pain) is a programme of rehabilitation that integrates educational self-management and coping strategies for people with joint pain with an individualised exercise regimen for each participant. The implementation of the programme will be conducted by the researcher as a certified facilitator by using Clinician's training manual for the ESCAPE-pain programme.
Study: NCT00805090

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sporanox
Description: 200 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Diclofenac Sodium
Description: 37.5 mg
Study: NCT01722162

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levocetirizine
Study: NCT04144348

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: mRNA-1653
Description: Sterile liquid for injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: mRNA-1653
Description: Sterile liquid for injection

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Sterile liquid for injection

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Sterile liquid for injection
Study: NCT04481789

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MT-1186
Description: Suspension

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MT-1186
Description: Suspension

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MT-1186
Description: Suspension

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rosuvastatin
Description: Tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sildenafil
Description: Tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Furosemide
Description: Tablets
Study: NCT03783585

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive behavioral therapy for insomnia
Description: The web-based CBT-I program is a 6-week interactive, online program that delivers typical CBT-I treatment techniques of stimulus control, sleep restriction, behavioral modifications, and cognitive restructuring.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive behavioral therapy for insomnia
Description: The web-based CBT-I program is a 6-week interactive, online program that delivers typical CBT-I treatment techniques of stimulus control, sleep restriction, behavioral modifications, and cognitive restructuring.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive behavioral therapy for insomnia + biweekly support
Description: Individuals randomized into the CBT-I + biweekly support will participate in CBT-I as described as well as a biweekly phone call or video call with research personnel for motivational interviewing.
Study: NCT02524886

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: GPi DBS with Medtronic electorde and Activa PC pulsegenerator
Description: The electric stimulation of 2 leads implanted in the Globus Pallidus internus

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: GPi DBS with Medtronic electorde and Activa PC pulsegenerator
Description: The electric stimulation of 2 leads implanted in the Globus Pallidus internus
Study: NCT00487006

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Serum Lab testing
Description: Serum Lab testing

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Serum Lab testing
Description: Serum Lab testing

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Serum Lab testing
Description: Serum Lab testing
Study: NCT03297918

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Respiratory muscle training
Description: The intervention is two-parted and includes weekly singing lessons in a choir, held by a professional instructor, with additional instructions for daily breathing exercise at home.
Study: NCT03039855

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TIARA valve and transapical delivery system
Description: Transcatheter mitral valve replacement
Study: NCT00721708

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Chicken broth
Description: one time dose of chicken broth obtained from 150g of chicken breast
Study: NCT04764877

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Osteopathic Manipulative Medicine
Description: Provided 15-20 minute long OMT session for patients in the OMT arm
Study: NCT04031547

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Transcranial Electrical Stimulation (tES)
Description: In tES, a mild electrical current is passed between two or more electrodes placed on the scalp.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Transcranial Electrical Stimulation (tES)
Description: In tES, a mild electrical current is passed between two or more electrodes placed on the scalp.
Study: NCT05014906

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Minocycline 45 MG
Description: 45 mg oral minocyclineonce daily vs 45mg oral minocycline once daily in combination with use of 15% azelaic acid

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Minocycline 45 MG
Description: 45 mg oral minocyclineonce daily vs 45mg oral minocycline once daily in combination with use of 15% azelaic acid
Study: NCT01722162

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levocetirizine
Study: NCT03762343

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ultrasound guided Greater occipital nerve block
Description: ultrasound guided Greater occipital nerve block with 2 ml of bupivacaine 0.5% (up to a maximum of 2 mg/kg) subcutaneous under ultrasound guidance in the greater occipital nerve region bilaterally.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: control group C
Description: Patient in this group will receive the intraoperative standard of care(intraoperative intravenous fentanyl and paracetamol)